IVR Clinical Concepts (www.ivrcc.com) is a technology company delivering patient registration, randomization and trial supply management (RTSM) and ePRO/eCOA via IVR/IMR/IWR for the electronic collection of patient/caregiver reported outcomes. The IVRCC System collects data as eSource and communicates in real-time seamlessly exchanging data with other eClinical Systems including OmniComm TrialMaster, Medidata RAVE and other EDC and CTM Systems. Much of the primary and secondary endpoint data for CNS, Behavioral Disorders, GI Disorders, and other therapeutics areas is collected from patient, caregiver and interviewer (Rater) reported outcomes. The overwhelming evidence is that collection of ePRO/eCOA data by electronic means vs. paper, combined with patient and site engagement reminders, results in more contemporaneous, complete, compliant and accurate data which is able to be accessed by study stakeholders in real-time.
This document provides an update on the Pediatric Vasculitis Initiative (PedVas) from its meeting at the 2015 CORD Rare Disease Conference. PedVas is an international collaboration between clinicians and researchers studying childhood vasculitis. It aims to support existing clinical networks through collection and analysis of biological samples and knowledge translation. The update describes two case studies of children diagnosed with vasculitis, preliminary clinical data on outcomes in pediatric systemic vasculitis, biomarker research identifying elevated S100A12 levels in active vasculitis, and gene expression profiling of samples collected through the initiative.
IMS Health Clinical Trial Optimization SolutionsQuintilesIMS
IMS Health's Linda T. Drumright, general manager, Clinical Trial Optimization Solutions presents at the 3rd Annual Patient Recruitment & Retention Summit 2014 - San Francisco, CA
This document discusses secondary data analysis and provides examples of large federal health surveys that can be used for secondary analysis, including NHANES and NHIS. It outlines strengths and limitations of secondary data analysis. Complex survey design must be accounted for, including statistical weighting, clustering, and stratification. Several statistical software programs are designed for analyzing complex survey data. The document concludes with a hypothetical case study using NHIS and EPA air pollution exposure data to study the relationship between acrolein levels and childhood asthma episodes.
Racing for results: lessons learnt in improving the efficiency of HIV VL and ...SystemOne
This document discusses strategies for improving the efficiency of delivering HIV viral load and early infant diagnosis test results from laboratories to clinics. Traditional paper-based reporting systems can result in delays and lost results. Newer electronic and mobile health platforms show promise in reducing turnaround times, but also face challenges from limited infrastructure in low-resource settings. Specifically, laboratory information systems, SMS messaging, and SMS printers are being used to deliver results digitally, with some programs reporting up to 50% reductions in turnaround times. However, merely delivering results is not enough - systems also need to ensure results are received and acted upon to improve patient outcomes.
Patient Blood Management: Impact of Quality Data on Patient OutcomesViewics
Patient blood management (PBM) has been proven to improve patient outcomes and save hospitals millions of dollars. Ensuring the quality of your data is central to decision making and critical to having a strong PBM program.
Would you like to learn how your organization can improve patient outcomes by implementing a PBM program based on accurate data?
If so, view this presentation by blood management expert Lance Trewhella. Lance presents how to develop a successful, evidence-based, multidisciplinary PBM program aimed at optimizing the care of patients who might need transfusion.
You’ll learn:
• Current recommendations for blood transfusion utilization
• The impact of quality data on PBM programs
• Best data practices in PBM
Tackling the U.S. Healthcare System’s Infectious Disease Management ProblemViewics
The United States healthcare system has a serious infectious disease management problem. The antibiotic resistance crisis is widespread, serious, costly, and deadly. Delays in pathogen identification lead to poor clinical outcomes, including increased mortality risk. And, optimally managing outbreaks is critical to health systems whose reimbursement is tied to the health of a population, such as ACOs.
Eleanor Herriman, MD, MBA, Chief Medical Informatics Officer at Viewics led an informative panel discussion with industry leaders on the issues surrounding the infectious disease management crisis. Margret Oethinger, MD, Ph.D., Medical Director of Providence Health & Services, and Susan E. Sharp, Ph.D., DABMM, FAAM, Regional Director of Microbiology and the Molecular Infectious Disease Laboratories, Department of Pathology, Kaiser Permanente and President-Elect, American Society for Microbiology cover the current state of infectious disease management in the U.S., and what can be done to improve it.
You’ll learn about:
• The magnitude of the U.S. health system’s infectious disease management problem
• The most serious concerns and trends for healthcare institutions and communities across the nation
• The most promising solutions to health systems’ most urgent infectious disease management challenges
This document provides an overview and agenda for an informational webinar on the NYS Health Innovation Challenge. The webinar will feature representatives from the NYS Department of Health and Health 2.0 who will describe the challenge, available data assets including SPARCS, QARR and cardiac reporting system data, and details about the challenge such as evaluation criteria and timeline. The challenge aims to create technology-driven solutions that enable various groups to explore quality, charges and costs data for medical procedures in NYS hospitals in order to increase usage of open health data, reduce healthcare costs, and empower consumers.
This document provides an update on the Pediatric Vasculitis Initiative (PedVas) from its meeting at the 2015 CORD Rare Disease Conference. PedVas is an international collaboration between clinicians and researchers studying childhood vasculitis. It aims to support existing clinical networks through collection and analysis of biological samples and knowledge translation. The update describes two case studies of children diagnosed with vasculitis, preliminary clinical data on outcomes in pediatric systemic vasculitis, biomarker research identifying elevated S100A12 levels in active vasculitis, and gene expression profiling of samples collected through the initiative.
IMS Health Clinical Trial Optimization SolutionsQuintilesIMS
IMS Health's Linda T. Drumright, general manager, Clinical Trial Optimization Solutions presents at the 3rd Annual Patient Recruitment & Retention Summit 2014 - San Francisco, CA
This document discusses secondary data analysis and provides examples of large federal health surveys that can be used for secondary analysis, including NHANES and NHIS. It outlines strengths and limitations of secondary data analysis. Complex survey design must be accounted for, including statistical weighting, clustering, and stratification. Several statistical software programs are designed for analyzing complex survey data. The document concludes with a hypothetical case study using NHIS and EPA air pollution exposure data to study the relationship between acrolein levels and childhood asthma episodes.
Racing for results: lessons learnt in improving the efficiency of HIV VL and ...SystemOne
This document discusses strategies for improving the efficiency of delivering HIV viral load and early infant diagnosis test results from laboratories to clinics. Traditional paper-based reporting systems can result in delays and lost results. Newer electronic and mobile health platforms show promise in reducing turnaround times, but also face challenges from limited infrastructure in low-resource settings. Specifically, laboratory information systems, SMS messaging, and SMS printers are being used to deliver results digitally, with some programs reporting up to 50% reductions in turnaround times. However, merely delivering results is not enough - systems also need to ensure results are received and acted upon to improve patient outcomes.
Patient Blood Management: Impact of Quality Data on Patient OutcomesViewics
Patient blood management (PBM) has been proven to improve patient outcomes and save hospitals millions of dollars. Ensuring the quality of your data is central to decision making and critical to having a strong PBM program.
Would you like to learn how your organization can improve patient outcomes by implementing a PBM program based on accurate data?
If so, view this presentation by blood management expert Lance Trewhella. Lance presents how to develop a successful, evidence-based, multidisciplinary PBM program aimed at optimizing the care of patients who might need transfusion.
You’ll learn:
• Current recommendations for blood transfusion utilization
• The impact of quality data on PBM programs
• Best data practices in PBM
Tackling the U.S. Healthcare System’s Infectious Disease Management ProblemViewics
The United States healthcare system has a serious infectious disease management problem. The antibiotic resistance crisis is widespread, serious, costly, and deadly. Delays in pathogen identification lead to poor clinical outcomes, including increased mortality risk. And, optimally managing outbreaks is critical to health systems whose reimbursement is tied to the health of a population, such as ACOs.
Eleanor Herriman, MD, MBA, Chief Medical Informatics Officer at Viewics led an informative panel discussion with industry leaders on the issues surrounding the infectious disease management crisis. Margret Oethinger, MD, Ph.D., Medical Director of Providence Health & Services, and Susan E. Sharp, Ph.D., DABMM, FAAM, Regional Director of Microbiology and the Molecular Infectious Disease Laboratories, Department of Pathology, Kaiser Permanente and President-Elect, American Society for Microbiology cover the current state of infectious disease management in the U.S., and what can be done to improve it.
You’ll learn about:
• The magnitude of the U.S. health system’s infectious disease management problem
• The most serious concerns and trends for healthcare institutions and communities across the nation
• The most promising solutions to health systems’ most urgent infectious disease management challenges
This document provides an overview and agenda for an informational webinar on the NYS Health Innovation Challenge. The webinar will feature representatives from the NYS Department of Health and Health 2.0 who will describe the challenge, available data assets including SPARCS, QARR and cardiac reporting system data, and details about the challenge such as evaluation criteria and timeline. The challenge aims to create technology-driven solutions that enable various groups to explore quality, charges and costs data for medical procedures in NYS hospitals in order to increase usage of open health data, reduce healthcare costs, and empower consumers.
Patient recruitment and retention in clinical trials is recognized as a major challenge. Over 80% of trials fail to enroll on time due to difficulties recruiting the required number of suitable patients. Recruitment strategies are often not considered early enough in the trial planning process. Effective recruitment requires realistic timelines, adequate budgets, and the use of multiple recruitment methods like investigator databases, clinician referrals, advertisements, and community outreach. Maintaining open communication with patients and providing convenience are important for retention. Recent approaches to improve recruitment include using professional recruitment providers, market research, informatics, and centralized recruiting systems.
Tracy Cadet seeks a position utilizing strong organizational and multi-tasking skills. She has over 10 years of experience in clinical data management, pharmacovigilance, and drug safety. Her background includes data entry, analysis, quality control, and regulatory reporting for adverse events. Cadet is proficient in Microsoft Office, databases such as Argus and ARISg, and has advanced knowledge of medical terminology and FDA regulations.
This document summarizes a seminar on data collection methods in practice-based research network (PBRN) research. It discusses previous topics covered in the seminar series, including what PBRNs are and how they function. Tonight's topics are on internet-based data collection tools in PBRN research and data collection methods, including the weekly return card method. This involves clinicians systematically recording observations about consecutive patients on a pocket-sized card. The document provides an example of a card study conducted in a PBRN on the effect of parental expectations on treating children with coughs. It also discusses electronic data collection tools, benefits and challenges, including using tablet computers, online surveys, and ensuring security when transmitting data.
2015 indicator reference guide viral load suppression at 12 months#GOMOJO, INC.
This document provides guidance on the indicator "Percentage of ART patients with a viral load result documented in the medical record within the past 12 months". It aims to monitor the proportion of patients on antiretroviral therapy (ART) who receive routine viral load testing to determine treatment effectiveness. The numerator is the number of ART patients with a documented viral load result in their medical record from the past 12 months. The denominator is the number of ART patients whose medical records were reviewed who have been on treatment for at least 6 months. Achieving high rates of routine viral load testing is important for sustaining treatment outcomes and reducing transmission at scale.
Advanced Lab Analytics for Patient Blood Management ProgramsViewics
Reports indicate that 30 – 70% of blood transfusions are inappropriate. Inappropriate blood transfusions put patients at increased risk of post-surgical infections, multi-system organ failure, longer hospital stays, and higher mortality rates. The transfusion guidelines most clinicians learned in their training are now outdated. As such, blood transfusion practices vary widely, and overutilization remains a major quality and cost problem.
Patient Blood Management (PBM) programs are designed to optimize the use of transfusions through a team-based approach, evidence-based guidelines, and algorithms that together guide decisions regarding specifically which patients and clinical procedures warrant blood products, and how much to transfuse. PBM programs have been quite successful in improving patient morbidity and mortality outcomes and generating millions of dollars in savings for hospitals.
Laboratory analytics can be an effective means of instituting restrictive transfusion programs, and advanced lab analytics can be critical in implementing PBM programs, as lab testing and tracking blood usage is central to decision making, changing behavior, and improving performance.
Watch a presentation by Dr. Eleanor Herriman, Chief Medical Informatics Officer at Viewics. She unveils a new suite of advanced analytics tools that support PBS and other restrictive blood management programs, enabling health systems to better leverage their valuable lab medicine assets and fully integrate this key service line into these programs.
You’ll learn:
• How inappropriate blood transfusions are burdening our healthcare system, and the need for better utilization management tools
• New guidelines restricting red blood cell transfusions
• The role of advanced lab analytics in PBM programs
• How Viewics is leveraging advanced lab analytics to help health systems more easily and cost-effectively implement PBM programs
2016 indicator reference guide viral load suppression at 12 months#GOMOJO, INC.
1) This indicator measures the percentage of ART patients with a viral load result documented within the past 12 months. Viral load testing is important for monitoring treatment effectiveness and preventing drug resistance.
2) The numerator is the number of ART patients (adults and children) with a viral load result documented in their medical record within the past 12 months. The denominator is the number of ART patients reviewed whose medical records were examined.
3) Achieving high rates of viral load testing is critical for monitoring treatment outcomes and scaling up HIV treatment programs. Support for viral load testing includes procurement of reagents, transportation of samples, and clinical mentoring at ART sites.
Best Practices for a Data-driven Approach to Test UtilizationViewics
Would you like to learn how data-driven interventions can improve laboratory test utilization in your organization? Would you like to hear about the impact that leading hospitals/health systems and managed care organizations have made through these interventions?
If so, you might be interested in this presentation by utilization management expert Dr. Michael Astion, Medical Director at the Department of Laboratories at Seattle Children’s Hospital and Clinical Professor of Laboratory Medicine at the University of Washington.
In this presentation, Dr. Astion discusses the current state of the misuse of laboratory testing in the United States and some of the interventions that are being implemented to improve it. He covers a number of common areas of unnecessary testing — from pure abuse to tests that could be useful but are ordered inappropriately.
You'll learn about:
• Two areas of laboratory testing where misordering of tests occur frequently
• Three interventions to improve the value of testing for patients
• The role of genetic counselors and other laboratory professionals in improving lab test ordering
• The national endeavor known as PLUGS, the Pediatric Laboratory Utilization Guidance Service
Revolutionizing Renal Care With Predictive Analytics for CKDViewics
Chronic Kidney Disease (CKD) is a common and growing condition, affecting about half of the Medicare population and of diabetics. In the United States, the lifetime risk of CKD for 30-year-olds is now greater than half, and the prevalence of CKD is projected to rise significantly over the next 15 years.
Current methods of predicting which CKD patients will progress to renal failure and require dialysis or transplant have low accuracy rates, causing great anxiety and suboptimal care. Without accurate risk prediction, many patients are over-treated, effectively wasting limited resources and negatively impacting outcomes. Conversely, other patients may receive inadequate treatment, restricting options to only the most costly and least desirable interventions.
Watch this on-demand webinar with Dr. Navdeep Tangri, developer of the Kidney Failure Risk Equation, which revolutionizes the way CKD patients are managed by leveraging laboratory data to accurately predict the risk of kidney failure in patients with CKD.
You’ll learn:
• How CKD is burdening our healthcare system, and the need for better care management tools
• How the Kidney Failure Risk Equation was researched, developed, and validated
• How Viewics is implementing CKD predictive analytics to automatically deliver risk information to clinicians and issue customized, educational reports to patients and clinicians
- Patient recruitment for clinical trials is a major challenge, estimated to be a $1.2-1.8 billion market. Recruitment costs average 6% of trial costs and are a primary factor in delays.
- Less than 5% of patients are aware of clinical trials, and only 2-3% actually enroll. However, over 90% of participants have a positive experience and would participate again.
- There is significant opportunity to improve recruitment through more patient-centric approaches leveraging data, technology, and analytics to identify more eligible patients and improve the recruitment process. However, this will require changes to traditional models.
Advanced Laboratory Analytics — A Disruptive Solution for Health SystemsViewics
Advanced laboratory analytics can provide a disruptive solution for health systems facing challenges under value-based care models. Laboratory data is well-suited for advanced analytics due to its timeliness, structured format, ubiquity across settings and providers, and predictive potential. Laboratory-based predictive algorithms and clinical decision support tools can help optimize outcomes like readmissions, adverse events, costs, and disease management. By leveraging laboratory data and analytics, health systems can better manage patient populations, make personalized medical decisions, and support value-based care goals of improving quality while reducing costs.
Basic Study Recruitment and Regulatory Issues: Which Methods are Appropriate?CTSI at UCSF
Presentation by Laurie Herraiz, RD, CCRP in May 2012 at CHR sponsored workshop on UCSF Campus. Topics include, basics of regulatory and recruitment, iMedrRIS application instructions, waivers of consent/authorization for recruitment purposes, examples of approved recruitment materials, and common challenges to recruitment.
AAA 2016 networking day final presentationsMike Harris
The document summarizes the results and updates from the NHS AAA Screening Programme. Some key points:
- Almost 1.3 million men were invited for screening, with an uptake of 79.5%
- Nearly 13,000 abdominal aortic aneurysms (AAA) larger than 3cm were detected, with a prevalence of 1.3%
- Options to extend surveillance intervals to biennially were presented, which could result in cost savings of over £600,000 per invited cohort.
- Evidence was presented on the risk of AAA progression in men with subaneurysmal aortas between 2.6-2.9cm, supporting potential rescreening of these men after 5 years.
With almost half of oncology studies failing due to a lack of patient retention, there is a critical need to develop more efficient and patient focused strategies. Jessica Thilaganathan at CRF Health sits down with International Clinical Trials to explain why electronic clinical outcome solutions could be the answer. (Published with permission of International Clinical Trials).
This document provides an overview of the drug approval and reimbursement timelines for several rare disease drugs in Canada, including Strensiq, Fabrazyme, Tegsedi, Onpattro, Vydaquel, Soliris, Trikafta, Zolgensma, Luxturna, and Nusinersen. For each drug, it outlines the key dates related to Health Canada approval, CADTH/INESSS submissions and recommendations, and pCPA negotiations. The document demonstrates how long the process can take to achieve public reimbursement for rare disease treatments in Canada.
Best Practices in Clinical Study RecruitmentCTSI at UCSF
This document discusses best practices in clinical study recruitment and retention. It covers:
1) Recruitment practices such as performing initial analyses of study design and site-specific factors, planning and budgeting for screen failures and protocol changes, and implementing a staged communication plan.
2) Retention practices like ensuring participants are well-informed, understanding their needs, and keeping communication open.
3) A proposed Participant Recruitment Service at UCSF to centralize recruitment efforts through activities like recruitment analysis, direct mailings to patient cohorts, and developing recruitment materials and resources.
This study aimed to compare the costs of diagnostic tests between urban and rural areas of Bangladesh. Interviews were conducted in Dhaka and 5 rural areas with 100 people in each location. The results found that diagnostic costs were on average 104% higher in Dhaka compared to rural areas. Rural residents had more faith in diagnostic tests and generally went to local practitioners for primary healthcare, while specialists in Dhaka sometimes recommended repeating tests done in rural areas. In conclusion, significant differences exist in diagnostic costs between urban and rural Bangladesh due to factors like technology, maintenance costs, and business interests.
This document summarizes a webinar on building Canada's strategy for access to rare drugs. Day 1 focuses on challenges to access. Dr. Cheryl Rockman-Greenberg discusses her work on hypophosphatasia (HPP), a rare bone disease. She outlines the different forms of HPP and clinical studies of asfotase alfa treatment. Asfotase alfa was approved in Canada for pediatric HPP but access challenges remain for adults. Real-world evidence is needed to understand natural history and inform treatment criteria for adults. The HPP patient registry collects global data on treatment effects, safety and outcomes to address knowledge gaps.
Tricks of the Trade: Patient Recruitment & Retention for Different Study TypesImperial CRS
In efforts to raise the bar for medical advancement, clinical trials are growing increasingly complex. This complexity, more often than not, leads to costly delays in enrollment. In this ebook, we'll take a look at 4 case studies for different study types, and examine the unique factors to consider during planning.
ACS NSQIP Best Practices Case studies volume 2 July 2010mart1971
This case study describes how Advocate Good Samaritan Hospital in Downers Grove, Illinois used an interdisciplinary team and Failure Mode and Effects Analysis (FMEA) process to address high outlier results for postoperative renal failure outcomes identified through their participation in ACS NSQIP. The team identified five areas for improvement in preoperative testing, bowel preparation instructions, fluid management in surgical holding, documentation of fluid intake and output, and surgeon communication. Changes were implemented including improved bowel preparation and hydration education, preoperative renal testing and standardized fluid orders for colorectal patients, and communication enhancements. These efforts resulted in a reduction of their observed to expected ratio for renal failure from 2.89 initially to 0.85 in their
QPS is a contract research organization that provides discovery, preclinical, and clinical development services including bioanalysis, DMPK, biomarkers, and early phase clinical research. It has facilities in Newark, DE, Taipei, Taiwan, and Springfield, MO that are GLP compliant. QPS supports clients through all phases of drug development with specialized services including bioanalysis, PK/PD analysis, ADME studies, and clinical research.
Aldo Rolfo, National Clinical Development Manager, Genesis Cancer Care, Austr...GenesisCareUK
A program that seeks to redefine best practice across the drivers of the GenesisCare business (Quality, Access and Efficiency) in order to deliver on their vision of “Innovating Healthcare. Transforming Lives.”
Patient recruitment and retention in clinical trials is recognized as a major challenge. Over 80% of trials fail to enroll on time due to difficulties recruiting the required number of suitable patients. Recruitment strategies are often not considered early enough in the trial planning process. Effective recruitment requires realistic timelines, adequate budgets, and the use of multiple recruitment methods like investigator databases, clinician referrals, advertisements, and community outreach. Maintaining open communication with patients and providing convenience are important for retention. Recent approaches to improve recruitment include using professional recruitment providers, market research, informatics, and centralized recruiting systems.
Tracy Cadet seeks a position utilizing strong organizational and multi-tasking skills. She has over 10 years of experience in clinical data management, pharmacovigilance, and drug safety. Her background includes data entry, analysis, quality control, and regulatory reporting for adverse events. Cadet is proficient in Microsoft Office, databases such as Argus and ARISg, and has advanced knowledge of medical terminology and FDA regulations.
This document summarizes a seminar on data collection methods in practice-based research network (PBRN) research. It discusses previous topics covered in the seminar series, including what PBRNs are and how they function. Tonight's topics are on internet-based data collection tools in PBRN research and data collection methods, including the weekly return card method. This involves clinicians systematically recording observations about consecutive patients on a pocket-sized card. The document provides an example of a card study conducted in a PBRN on the effect of parental expectations on treating children with coughs. It also discusses electronic data collection tools, benefits and challenges, including using tablet computers, online surveys, and ensuring security when transmitting data.
2015 indicator reference guide viral load suppression at 12 months#GOMOJO, INC.
This document provides guidance on the indicator "Percentage of ART patients with a viral load result documented in the medical record within the past 12 months". It aims to monitor the proportion of patients on antiretroviral therapy (ART) who receive routine viral load testing to determine treatment effectiveness. The numerator is the number of ART patients with a documented viral load result in their medical record from the past 12 months. The denominator is the number of ART patients whose medical records were reviewed who have been on treatment for at least 6 months. Achieving high rates of routine viral load testing is important for sustaining treatment outcomes and reducing transmission at scale.
Advanced Lab Analytics for Patient Blood Management ProgramsViewics
Reports indicate that 30 – 70% of blood transfusions are inappropriate. Inappropriate blood transfusions put patients at increased risk of post-surgical infections, multi-system organ failure, longer hospital stays, and higher mortality rates. The transfusion guidelines most clinicians learned in their training are now outdated. As such, blood transfusion practices vary widely, and overutilization remains a major quality and cost problem.
Patient Blood Management (PBM) programs are designed to optimize the use of transfusions through a team-based approach, evidence-based guidelines, and algorithms that together guide decisions regarding specifically which patients and clinical procedures warrant blood products, and how much to transfuse. PBM programs have been quite successful in improving patient morbidity and mortality outcomes and generating millions of dollars in savings for hospitals.
Laboratory analytics can be an effective means of instituting restrictive transfusion programs, and advanced lab analytics can be critical in implementing PBM programs, as lab testing and tracking blood usage is central to decision making, changing behavior, and improving performance.
Watch a presentation by Dr. Eleanor Herriman, Chief Medical Informatics Officer at Viewics. She unveils a new suite of advanced analytics tools that support PBS and other restrictive blood management programs, enabling health systems to better leverage their valuable lab medicine assets and fully integrate this key service line into these programs.
You’ll learn:
• How inappropriate blood transfusions are burdening our healthcare system, and the need for better utilization management tools
• New guidelines restricting red blood cell transfusions
• The role of advanced lab analytics in PBM programs
• How Viewics is leveraging advanced lab analytics to help health systems more easily and cost-effectively implement PBM programs
2016 indicator reference guide viral load suppression at 12 months#GOMOJO, INC.
1) This indicator measures the percentage of ART patients with a viral load result documented within the past 12 months. Viral load testing is important for monitoring treatment effectiveness and preventing drug resistance.
2) The numerator is the number of ART patients (adults and children) with a viral load result documented in their medical record within the past 12 months. The denominator is the number of ART patients reviewed whose medical records were examined.
3) Achieving high rates of viral load testing is critical for monitoring treatment outcomes and scaling up HIV treatment programs. Support for viral load testing includes procurement of reagents, transportation of samples, and clinical mentoring at ART sites.
Best Practices for a Data-driven Approach to Test UtilizationViewics
Would you like to learn how data-driven interventions can improve laboratory test utilization in your organization? Would you like to hear about the impact that leading hospitals/health systems and managed care organizations have made through these interventions?
If so, you might be interested in this presentation by utilization management expert Dr. Michael Astion, Medical Director at the Department of Laboratories at Seattle Children’s Hospital and Clinical Professor of Laboratory Medicine at the University of Washington.
In this presentation, Dr. Astion discusses the current state of the misuse of laboratory testing in the United States and some of the interventions that are being implemented to improve it. He covers a number of common areas of unnecessary testing — from pure abuse to tests that could be useful but are ordered inappropriately.
You'll learn about:
• Two areas of laboratory testing where misordering of tests occur frequently
• Three interventions to improve the value of testing for patients
• The role of genetic counselors and other laboratory professionals in improving lab test ordering
• The national endeavor known as PLUGS, the Pediatric Laboratory Utilization Guidance Service
Revolutionizing Renal Care With Predictive Analytics for CKDViewics
Chronic Kidney Disease (CKD) is a common and growing condition, affecting about half of the Medicare population and of diabetics. In the United States, the lifetime risk of CKD for 30-year-olds is now greater than half, and the prevalence of CKD is projected to rise significantly over the next 15 years.
Current methods of predicting which CKD patients will progress to renal failure and require dialysis or transplant have low accuracy rates, causing great anxiety and suboptimal care. Without accurate risk prediction, many patients are over-treated, effectively wasting limited resources and negatively impacting outcomes. Conversely, other patients may receive inadequate treatment, restricting options to only the most costly and least desirable interventions.
Watch this on-demand webinar with Dr. Navdeep Tangri, developer of the Kidney Failure Risk Equation, which revolutionizes the way CKD patients are managed by leveraging laboratory data to accurately predict the risk of kidney failure in patients with CKD.
You’ll learn:
• How CKD is burdening our healthcare system, and the need for better care management tools
• How the Kidney Failure Risk Equation was researched, developed, and validated
• How Viewics is implementing CKD predictive analytics to automatically deliver risk information to clinicians and issue customized, educational reports to patients and clinicians
- Patient recruitment for clinical trials is a major challenge, estimated to be a $1.2-1.8 billion market. Recruitment costs average 6% of trial costs and are a primary factor in delays.
- Less than 5% of patients are aware of clinical trials, and only 2-3% actually enroll. However, over 90% of participants have a positive experience and would participate again.
- There is significant opportunity to improve recruitment through more patient-centric approaches leveraging data, technology, and analytics to identify more eligible patients and improve the recruitment process. However, this will require changes to traditional models.
Advanced Laboratory Analytics — A Disruptive Solution for Health SystemsViewics
Advanced laboratory analytics can provide a disruptive solution for health systems facing challenges under value-based care models. Laboratory data is well-suited for advanced analytics due to its timeliness, structured format, ubiquity across settings and providers, and predictive potential. Laboratory-based predictive algorithms and clinical decision support tools can help optimize outcomes like readmissions, adverse events, costs, and disease management. By leveraging laboratory data and analytics, health systems can better manage patient populations, make personalized medical decisions, and support value-based care goals of improving quality while reducing costs.
Basic Study Recruitment and Regulatory Issues: Which Methods are Appropriate?CTSI at UCSF
Presentation by Laurie Herraiz, RD, CCRP in May 2012 at CHR sponsored workshop on UCSF Campus. Topics include, basics of regulatory and recruitment, iMedrRIS application instructions, waivers of consent/authorization for recruitment purposes, examples of approved recruitment materials, and common challenges to recruitment.
AAA 2016 networking day final presentationsMike Harris
The document summarizes the results and updates from the NHS AAA Screening Programme. Some key points:
- Almost 1.3 million men were invited for screening, with an uptake of 79.5%
- Nearly 13,000 abdominal aortic aneurysms (AAA) larger than 3cm were detected, with a prevalence of 1.3%
- Options to extend surveillance intervals to biennially were presented, which could result in cost savings of over £600,000 per invited cohort.
- Evidence was presented on the risk of AAA progression in men with subaneurysmal aortas between 2.6-2.9cm, supporting potential rescreening of these men after 5 years.
With almost half of oncology studies failing due to a lack of patient retention, there is a critical need to develop more efficient and patient focused strategies. Jessica Thilaganathan at CRF Health sits down with International Clinical Trials to explain why electronic clinical outcome solutions could be the answer. (Published with permission of International Clinical Trials).
This document provides an overview of the drug approval and reimbursement timelines for several rare disease drugs in Canada, including Strensiq, Fabrazyme, Tegsedi, Onpattro, Vydaquel, Soliris, Trikafta, Zolgensma, Luxturna, and Nusinersen. For each drug, it outlines the key dates related to Health Canada approval, CADTH/INESSS submissions and recommendations, and pCPA negotiations. The document demonstrates how long the process can take to achieve public reimbursement for rare disease treatments in Canada.
Best Practices in Clinical Study RecruitmentCTSI at UCSF
This document discusses best practices in clinical study recruitment and retention. It covers:
1) Recruitment practices such as performing initial analyses of study design and site-specific factors, planning and budgeting for screen failures and protocol changes, and implementing a staged communication plan.
2) Retention practices like ensuring participants are well-informed, understanding their needs, and keeping communication open.
3) A proposed Participant Recruitment Service at UCSF to centralize recruitment efforts through activities like recruitment analysis, direct mailings to patient cohorts, and developing recruitment materials and resources.
This study aimed to compare the costs of diagnostic tests between urban and rural areas of Bangladesh. Interviews were conducted in Dhaka and 5 rural areas with 100 people in each location. The results found that diagnostic costs were on average 104% higher in Dhaka compared to rural areas. Rural residents had more faith in diagnostic tests and generally went to local practitioners for primary healthcare, while specialists in Dhaka sometimes recommended repeating tests done in rural areas. In conclusion, significant differences exist in diagnostic costs between urban and rural Bangladesh due to factors like technology, maintenance costs, and business interests.
This document summarizes a webinar on building Canada's strategy for access to rare drugs. Day 1 focuses on challenges to access. Dr. Cheryl Rockman-Greenberg discusses her work on hypophosphatasia (HPP), a rare bone disease. She outlines the different forms of HPP and clinical studies of asfotase alfa treatment. Asfotase alfa was approved in Canada for pediatric HPP but access challenges remain for adults. Real-world evidence is needed to understand natural history and inform treatment criteria for adults. The HPP patient registry collects global data on treatment effects, safety and outcomes to address knowledge gaps.
Tricks of the Trade: Patient Recruitment & Retention for Different Study TypesImperial CRS
In efforts to raise the bar for medical advancement, clinical trials are growing increasingly complex. This complexity, more often than not, leads to costly delays in enrollment. In this ebook, we'll take a look at 4 case studies for different study types, and examine the unique factors to consider during planning.
ACS NSQIP Best Practices Case studies volume 2 July 2010mart1971
This case study describes how Advocate Good Samaritan Hospital in Downers Grove, Illinois used an interdisciplinary team and Failure Mode and Effects Analysis (FMEA) process to address high outlier results for postoperative renal failure outcomes identified through their participation in ACS NSQIP. The team identified five areas for improvement in preoperative testing, bowel preparation instructions, fluid management in surgical holding, documentation of fluid intake and output, and surgeon communication. Changes were implemented including improved bowel preparation and hydration education, preoperative renal testing and standardized fluid orders for colorectal patients, and communication enhancements. These efforts resulted in a reduction of their observed to expected ratio for renal failure from 2.89 initially to 0.85 in their
QPS is a contract research organization that provides discovery, preclinical, and clinical development services including bioanalysis, DMPK, biomarkers, and early phase clinical research. It has facilities in Newark, DE, Taipei, Taiwan, and Springfield, MO that are GLP compliant. QPS supports clients through all phases of drug development with specialized services including bioanalysis, PK/PD analysis, ADME studies, and clinical research.
Aldo Rolfo, National Clinical Development Manager, Genesis Cancer Care, Austr...GenesisCareUK
A program that seeks to redefine best practice across the drivers of the GenesisCare business (Quality, Access and Efficiency) in order to deliver on their vision of “Innovating Healthcare. Transforming Lives.”
Altasciences Clinical Research offers comprehensive early stage drug development services including Phase I/II clinical trials, bioanalytical services, clinical data management, biostatistics, and pharmacokinetic/pharmacodynamic analysis. They have facilities in the US and Canada with over 600 beds for clinical trials. Altasciences specializes in areas like abuse liability, biosimilars, and cognitive testing and has partnerships to complement their service offerings. Patient safety is their top priority with 24/7 medical coverage and emergency response procedures.
Vince & Associates Clinical Research has been providing clinical research services for 15 years. They have an experienced team focusing on quality research data while also prioritizing speed, responsiveness, and accountability for clients. They operate using the Physician Research Model where studies are led by principal investigators involved in all aspects of trials. This approach and their expertise in special populations has led to long-term contracts with the FDA and NIDA.
The document discusses strategies for developing a reimbursement case for molecular diagnostic tests early in development. It emphasizes designing analytic and clinical validity studies to demonstrate test accuracy and association with clinical conditions. Clinical utility studies should show how test results impact patient management, outcomes, and healthcare costs. Randomized controlled trials provide the strongest evidence but alternative study designs like prospective observational studies and decision modeling may also support reimbursement. The goal is to generate evidence of a test's medical necessity and value to payers from an early stage.
Developing the Reimbursement Story 2016-03-10Lyssa Friedman
The document discusses strategies for developing a reimbursement case for molecular diagnostic tests early in development. It emphasizes designing analytic and clinical validity studies to demonstrate test accuracy and association with clinical conditions. Clinical utility studies should show how test results impact patient management, outcomes, and healthcare costs. Randomized controlled trials provide the strongest evidence but alternative study designs like prospective observational studies and decision modeling may also support reimbursement. The goal is to generate evidence of a test's medical necessity from the intended patient population to achieve coverage and payment.
Registry Participation 101: A Step-by-Step Guide to What You Really Need to K...Wellbe
This document provides an overview of registry participation and collecting patient-reported outcome measures through a registry. It discusses the University of Wisconsin's process for collecting PROs in their orthopedic clinics in two phases: a pilot phase and a full implementation phase. The pilot involved collecting PROs in 6 clinics using Epic and tablet computers. Lessons learned included that an integrated tablet/portal solution and coordinated project management were important. The full implementation will expand PRO collection to all orthopedic locations and improve reporting automation.
Sagar Paulkar has over 10 years of experience in clinical research and testing electronic data capture software. He currently works as a Clinical Test Engineer for Medrio, where he tests new versions of their electronic data capture software and ensures compliance with regulations. Previously he worked as a Clinical Research Coordinator conducting multiple oncology trials simultaneously and coordinating clinical trials. He has extensive training in clinical research and has worked on over 15 clinical trials covering various therapeutic areas.
This document discusses quality improvement in healthcare. It begins by posing questions about defining quality, what quality improvement is, and how quality can be improved. It then discusses the safety paradox in healthcare - that despite highly trained staff and technology, errors are common and patients are frequently harmed. Several studies on adverse event rates in hospitals are summarized. The document discusses concepts for safety and quality improvement like reliability, variation, measurement, and change management. It provides examples of quality improvement tools and approaches like process mapping, care bundles, measurement, and the PDSA (Plan-Do-Study-Act) cycle. Overall, the document provides an overview of key issues and approaches related to quality and safety in healthcare.
Find eligible patients that fit your protocol faster, identify and secure proven and/or new sites, forecast and measure progress more efficiency. With Covance's proprietary data, your program hits its mark.
Methods for Observational Comparative Effectiveness Research on Healthcare De...Marion Sills
Research Objective: The SAFTINet project was funded by the AHRQ to build a distributed network of existing clinical and claims data that would support comparative effectiveness research (CER), with a focus on underserved populations and healthcare delivery system (HDS) characteristics. Observational research methods are appropriate, but require detailed protocols with a priori hypotheses and analytic plans. SAFTINet research specifically concerns the effects of a discrete set of HDS features (those often included in Patient-Centered Medical Home (PCMH) models) on health outcomes for primary care patients with asthma, hypertension, and hypercholesterolemia. Our objective is to present a description of this study’s measurement challenges, and to specify a priori hypotheses, analytic strategies, and plans for addressing bias and confounding for our asthma cohorts.
Study Design: An observational, longitudinal cohort study of primary care patients with asthma, with both secondary use of existing clinical and claims data and primary data collection for HDS features and patient- reported outcomes.
Population Studied: Our sample consists of 59 primary care practices in 5 healthcare organizations in Colorado, Utah and Tennessee; all practices serve underserved populations. These practices care for about 275,000 patients per year, of whom an estimated 22,000 have a diagnosis of asthma.
Principal Findings: We will present the processes used to define and measure the HDS features, covariates and asthma outcomes, along with planned analysis. Challenges include valid measurement of a multi-faceted HDS “exposure” variable, the inability to identify exposure onset, and the non-dichotomous nature of HDS characteristics. To measure HDS characteristics, we created a practice-level survey assessing 9 PCMH domains, including care coordination, specialty care and mental health integration, and patient-centeredness, as well as asthma-specific HDS characteristics (e.g., the use of asthma registries). Asthma outcomes included (1) those available as a result of routine electronic documentation of clinical care and claims administration (utilization indicative of an exacerbation), and (2) patient reported outcomes tools (Asthma Control Test). We used directed acyclic graphs to identify potential confounders of the relationship between HDS characteristics and asthma control, as well as other potential biases. The analytic plan is based on linear mixed effects models. Perspectives of the CER team, the technology team and the community engagement group were considered in the operationalization of all variables.
Conclusions: The design of rigorous observational CER observational CER should recognize the need for an intense planning phase. In accordance with good practice guidance for observational studies, an important component of the planning phase is to disseminate and obtain feedback on the research design in advance of its conduct.
Patrick Jordan has over 30 years of experience in clinical research across various therapeutic areas and phases of research. He has worked as a clinical research associate and clinical trial coordinator, ensuring adherence to regulations and driving subject recruitment. His background includes experience in oncology, hematology, medical devices, and in vitro diagnostics. He aims to identify issues and resolve them appropriately to ensure the integrity of clinical data and safety of trial subjects.
Altasciences Clinical Research offers comprehensive Phase I/II drug development services including clinical trials, bioanalysis, data management, biostatistics, and regulatory support. They have facilities in the US and Canada with over 600 beds and can rapidly recruit from a database of over 225,000 volunteers. Altasciences focuses on customized solutions and meeting timelines to provide value to their pharmaceutical and biotech customers.
This document describes the Pediatrix Clinical DataWarehouse and its role in quality improvement initiatives for neonatal medicine. The Clinical DataWarehouse contains clinical data on over 700,000 patients and is one of the largest databases for neonatal outcomes. Data from electronic medical records is extracted and analyzed to identify areas for improvement. Quality improvement projects are developed and tracked using the QualitySteps system. Analyzing outcomes data allows Pediatrix to benchmark performance and drive continuous quality improvement that improves patient care.
The document discusses barriers and solutions to adopting diagnostic technologies in healthcare. It provides examples of diagnostic technologies that have been successfully adopted in the UK, such as Coaguchek for INR testing and faecal calprotectin testing. Both faced initial barriers but were able to demonstrate benefits like improved patient outcomes and efficiency. The document outlines tips for implementing diagnostics, such as collecting baseline data, gaining stakeholder support, and clearly defining the patient pathway and expected impact. Overall it advocates that diagnostic technologies can help address gaps in healthcare if barriers are overcome and benefits are demonstrated.
Altasciences Clinical Research offers comprehensive Phase I/II drug development services including clinical trials, bioanalysis, data management, biostatistics, and regulatory support. They have facilities in the US and Canada with over 600 beds and can rapidly recruit from a database of over 225,000 volunteers. Altasciences is committed to quality, safety, and compliance in conducting clinical trials to help customers develop new drugs.
Nurse scientists serve as knowledge brokers by linking researchers and decision makers. They facilitate interaction between these groups to support evidence-based decision making in healthcare. Nurse scientists require extensive knowledge in their specialty areas and perform research by developing solutions, running experiments, and applying for grants. Their work involves producing and disseminating knowledge for government agencies, universities, and private organizations. Nurse scientists influence nursing practice by assisting with workforce planning, setting standards and processes, and designing systems to measure and improve quality of care.
Automated Abstracting - NCRA San Antonio 2015Victor Brunka
Artificial intelligence can help automate the process of completing cancer registry abstracts. Recent successes in automating casefinding from pathology and imaging reports and extracting standardized data show promise. Continued progress in natural language processing, along with consolidation of diverse health records into a common data architecture, may allow auto-population of most abstract fields with high accuracy and completeness. This would enhance quality and timeliness of cancer reporting while reducing costs. The registry's role then focuses on complex tasks, maintaining standards and oversight.
Inflammatory Bowel Disease Drug Development Solutions Covance
Overcome unmet needs in IBD clinical development with an experienced and trusted partner There have been seven approved drugs for inflammatory bowel disease (IBD), comprising of ulcerative colitis and Crohn's disease, in the past decade. However, there remains a significant unmet need: current drugs typically induce remission in less than half of patients. Due to this need there is an increased interest in developing new IBD therapies and a concomitant increase in competition for trial sites and eligible patients.
Similar to IVR Clinical Concepts RTSM & ePRO/eCOA eSource Solutions (20)
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
The skin is the largest organ and its health plays a vital role among the other sense organs. The skin concerns like acne breakout, psoriasis, or anything similar along the lines, finding a qualified and experienced dermatologist becomes paramount.
Nano-gold for Cancer Therapy chemistry investigatory projectSIVAVINAYAKPK
chemistry investigatory project
The development of nanogold-based cancer therapy could revolutionize oncology by providing a more targeted, less invasive treatment option. This project contributes to the growing body of research aimed at harnessing nanotechnology for medical applications, paving the way for future clinical trials and potential commercial applications.
Cancer remains one of the leading causes of death worldwide, prompting the need for innovative treatment methods. Nanotechnology offers promising new approaches, including the use of gold nanoparticles (nanogold) for targeted cancer therapy. Nanogold particles possess unique physical and chemical properties that make them suitable for drug delivery, imaging, and photothermal therapy.
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Giloy in Ayurveda - Classical Categorization and SynonymsPlanet Ayurveda
Giloy, also known as Guduchi or Amrita in classical Ayurvedic texts, is a revered herb renowned for its myriad health benefits. It is categorized as a Rasayana, meaning it has rejuvenating properties that enhance vitality and longevity. Giloy is celebrated for its ability to boost the immune system, detoxify the body, and promote overall wellness. Its anti-inflammatory, antipyretic, and antioxidant properties make it a staple in managing conditions like fever, diabetes, and stress. The versatility and efficacy of Giloy in supporting health naturally highlight its importance in Ayurveda. At Planet Ayurveda, we provide a comprehensive range of health services and 100% herbal supplements that harness the power of natural ingredients like Giloy. Our products are globally available and affordable, ensuring that everyone can benefit from the ancient wisdom of Ayurveda. If you or your loved ones are dealing with health issues, contact Planet Ayurveda at 01725214040 to book an online video consultation with our professional doctors. Let us help you achieve optimal health and wellness naturally.
Discover the benefits of homeopathic medicine for irregular periods with our guide on 5 common remedies. Learn how these natural treatments can help regulate menstrual cycles and improve overall menstrual health.
Visit Us: https://drdeepikashomeopathy.com/service/irregular-periods-treatment/
2. Agenda
• Introduction
• IVR Clinical Concepts Company History
• Product Services
• Reports, Notification, Exports
• Customer Care (Helpdesk)
3. IVRCC History & Timeline
2010
Administrative
& sales HQ in
NY, dedicated
IVRS staff in
Boca Raton, FL
continual system
and security
upgrades
Expand
mobile IMR
device
usability,
better user
interface, web-
hosting,
security
2013
2015
Continue
growth,
improvement
and client
education
1991 1996 2003 2004 2006 2007 2008 2009 2010 2013 2015
Expand to
IWRS, for
better subject
and trial staff
use
2009
2008
Acquire IVR
Concepts –
platform &
process
upgrades,
SOPs, security
improvements
IVR Clinical
concepts
incorporate,
FDA Guidance
accepting data
meeting ALCOA
specs
2007
2006
IVR Concepts, LLC,
interactive web
board for trial staff,
to enter patient
information, PINs,
inclusion/exclusion,
demographics,& for
EDC integration
Passive web
board - trial
personnel to
access their
subject activity
information
directly
2004
2003
Partnership with
Phone Interactive
Communications
Co. (PICC), a Boca
Raton, FL platform
and IVR service
provider.
Fax/IVR
integration,
alerts/
notifications
1996
1991
Trademark for
early iteration of
new solution,
TeleDiary™
ediary, for data
collection from
subjects
2017
Deploy mobile
site tablets for
Rater evaluation,
continued
enhancement of
patient
engagement
2016
2016
4. Core Competencies of IVRS-IWRS
Screening,
Registration,
Randomization
CTM
Management
eCOA, ePRO eIntegration
• Subject Recruitment, Screening, Registration, Randomization
• Clinical Trial Material (drug-device) Supply, Dispensation
– Inventory Management, Accountability
• Electronic Clinical Outcomes Assessments (eCOA) & Electronic
Subject Reported Outcomes (ePRO)
• Integration with Electronic Data Capture (EDC), Clinical Trial
Management Systems (CTMS), other electronic systems, etc.
• Standard and custom Reporting, Notifications - alerts, Data
Exports
Reporting
Notifications
Data Exports
5. IVRCC’s: IVRS-IWRS Features
• Extensive Clinical Study Experience, IVR/IWR custom coding, with fast
deployments
• PIN and passcode secured, secure hosting and advanced security
protocols, SSL encrypted communication protocol and 21CFR part11 &
HIPAA compliant
• SaaS - No software maintenance, or programming by client
• Support BYOD - No proprietary hardware investment: telephones,
computers, mobile devices
• Redundancy (IP, servers, facilities), tested and proven backup systems and
protocols, strategically co-located carrier facilities
• Scripts translated into virtually any written and spoken languages/dialects
• IVRS: Large simultaneous call volume capacity, international and toll-free
24/7/365 subject access via phone, or cell phone, skype
• IWRS: Scalable, access via virtually all internet connected devices -
PCs/Macs, IE, Chrome, Firefox, Safari etc. browsers, with website formatting
for smartphones and tablets, iOS and Android
7. Randomization
95% of studies include randomization
• Single randomization
list for entire study
• Randomization list by
country
• Randomization list by
site
• Randomization
stratified by location,
gender, level of
condition, age, etc.
• Minimization
techniques
• Custom/Client specific
algorithms
• Experience with
dynamic technique
• Other, e.g. Sequential
Parallel Comparison
Design (SPCD):
Blocked
Randomization
Stratification
Dynamic
Randomization
Coordinate
with CTM
Dispensation
Multiple Factors Desired Balance Assign Treatment
Coordinate
real-time, data
exchange with EDC
9. CTM Management Services
Manage, track and report
• Release initial supply allotments of study materials to activated sites
• Multiple supply models and management at central, regional and site inventories
• Project inventory needs per supply timelines and level of activity in different
countries, sites
• Inventory availability following shipment and treatment allocation
• Dispensing and titration management, accommodating real-time parameters,
investigator determinations, previous treatments and branched subject response
entries, adaptive trials
• On Demand Reports, real-time notifications appropriate to user categories
• Reviews and actions based on Expiry dates/product recall
• Continuous human intervention oversight provided by IVRCC staff
• On Demand Unblinding/Emergency Code Break system for restricted users
• Provide Clinical Trials Supply Management and Integration with other CTMS
applications
10. CTM Accountability
Distribution Depot to Depot
Depot to site
Dispensation Subject randomization
and pack allocation
Accountability Subject dispensing
and return documentation
Reconciliation Review and confirmation
of accountability data
Returns Management of return
shipments
Destruction Destruction confirmation
Clinical Trial Material supply management
system tracks from central to multiple
regional depots to point of allocation to a
subject.
CTM Accountability system picks up at this
point and tracks back from a subject until
final resolution of CTM is completed.
12. ePRO and Subject Data
Many Types of Information
• Medication Compliance
• Time/Date of events
• Modality (voice/web) Preferences
• Quality of Life (QoL)
– Mood
– Ability to perform certain
physical/cognitive tasks
• Self Reported Symptoms
• Work and Productivity
• Efficacy of CTM
• Subject Satisfaction
• Safety Side effects
Validated Instruments and
Novel Questionnaires
• Numeric Scales
• YES/NO Questions
• Multiple Choice
• Verbal Rating Scales
• Visual Analog Scales (VAS)
• Free text
• Body Diagrams
• Dynamic Branching
• Rater Evaluations
• ….and more
20. Scheduled, or on
demand
• Entire data-
base, or partial,
data, metadata
• End of study
final archive
available for
Sponsor, CRO
and sites, by
permission
• Electronic File
• Burnt to CD
Reporting, Notification, Exports
Real-time tracking via
the web
• Standard and
custom designed for
each study
• Reporting details
according to users’
assigned role-based
permissions
• Viewable, sortable &
filterable,
downloadable,
printable, exportable
to Excel
Reports
Confirmation of an
event, or NON-
event
• Fax, text, phone
call and/or email
– to site, medical
monitor, CRA,
study manager
even ePRO
subjects
• Occur as the result
of any study event
– Randomization
confirmation
– Supply shipment
– Supply reorder
– Diary reminder
– Lack of diary
compliance
Notifications
Fax and/or email
• Status reporting,
scheduled for run
at pre-defined time
intervals (daily,
weekly, monthly)
and sent via FAX
or Email
− Cumulative subject
or site tracking
information
− Projections
− Custom Reporting
Batch Reports Exports
21. Study Snapshot Chart
Site Enrollment Status Report
Drug Dispensing by Patient and Visit: PROTOCOL #CRW1007
23. Study Snapshot Chart & Graph
Subject Status - Randomization Report
Drug Dispensing by Patient and Visit: PROTOCOL #CRW1007
24. Study Snapshot Chart
Client Subject Status and Diary Compliance Report
Drug Dispensing by Patient and Visit: PROTOCOL #CRW1007
25. Study Snapshot eMail
Drug Dispensing by Patient and Visit: PROTOCOL #CRW1007
From: IVRCC Snapshot [mailto: @ivrcc.com]
Sent: Tuesday, August 20, 2013 10:05 AM
To: Nancy Hudak
Subject: - Study Snapshot - Week 18 of enrollment
Attached is the study snapshot report for the study.
Feasibility of a Using a Structured Daily Diary to Assess…
Enrollment started on April 16, 2013 with target enrollment of 90 subjects in 72
weeks.
At current enrollment rate of 2.00 subjects per week, it is estimated to enroll the
remaining 55 subjects in 27 weeks, February 2014
At best enrollment rate of 7.00 subjects per week, it is estimated to enroll the
remaining 55 subjects in 11 weeks, November 2013
31. Subject Diary History with Payments
Drug Dispensing by Patient and Visit: PROTOCOL #CRW1007
Diary History
Modality Day Date Progress
Incomp
lete
Section
Closed
Compens
ation
Bonus Lottery
Reason for
Missed Diary
Web 1 05/15/13 Complete 16-May 03:12 $2.00
Web 2 05/16/13 Not Started 17-May 08:30 $0.00
Web 3 05/17/13 Complete 18-May 00:46 $2.00 3
Web 4 05/18/13 Complete 19-May 01:19 $2.00 $25.00
Web 5 05/19/13 Complete 19-May 23:48 $2.00
Web 6 05/20/13 Complete 21-May 02:32 $2.00
Web 7 05/21/13 Complete 21-May 23:40 $2.00
Web 8 05/22/13 Complete 23-May 00:57 $2.00
Web 9 05/23/13 Complete 24-May 00:05 $2.00 $5.00
Web 10 05/24/13 Complete 25-May 02:30 $2.00
Web 11 05/25/13 Complete 26-May 00:37 $3.00
Web 12 05/26/13 Complete 27-May 01:48 $3.00
Web 13 05/27/13 Complete 27-May 22:22 $3.00
Web 14 05/28/13 Complete 28-May 23:36 $3.00
Web 15 05/29/13 Complete 30-May 00:46 $3.00 $5.00
Web 16 05/30/13 Complete 30-May 23:18 $3.00
Web 17 05/31/13 Complete 01-Jun 00:46 $3.00
Web 18 06/01/13 Complete 02-Jun 01:57 $4.00 $5.00
Web 19 06/02/13 Complete 03-Jun 01:08 $4.00
Web 20 06/03/13 Complete 04-Jun 00:30 $4.00 $5.00
Web 21 06/04/13 Complete 05-Jun 00:29 $4.00
Web 22 06/05/13 Complete 05-Jun 21:27 $4.00
Web 23 06/06/13 Complete 07-Jun 00:06 $4.00
Web 24 06/07/13 Complete 07-Jun 21:46 $4.00
Web 25 06/08/13 Incomplete E 09-Jun 08:30 ($1.00)
Web 26 06/09/13 Complete 10-Jun 01:03 $5.00 7
Web 27 06/10/13 Complete 11-Jun 01:34 $5.00
Web 28 06/11/13 Complete 12-Jun 02:58 $5.00
Web 29 06/12/13 Complete 12-Jun 20:10 $5.00
Web 30 06/13/13 Complete 14-Jun 00:14 $5.00
Diary History – Subject 10407
32. Diary Compliance Grid
Drug Dispensing by Patient and Visit: PROTOCOL #CRW1007
Close
Site:
All Sites
Subject: Modality:
(All)
Modality #:
(All)
Subject Modality # Started 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
10401 Phone 1 04/16/2011
10401 Web 2 05/21/2011
10402 Phone 1 04/30/2011
10403 Web 1 04/30/2011
10404 Web 1 05/02/2011
10405 Web 1 05/08/2011
10405 Phone 2 06/10/2011
10406 Web 1 05/15/2011
10406 Phone 2 06/17/2011
10407 Phone 1 06/05/2011
10407 Web 2 07/08/2011
10408 Phone 1 06/05/2011
10408 Web 2 07/09/2011
10409 Phone 1 06/17/2011
10410 Web 1 06/24/2011
10411 Web 1 06/25/2011
10412 Phone 1 06/27/2011
10413 Phone 1 07/03/2011
11901 Phone 1 06/14/2011
11902 Web 1 06/17/2011
11903 Phone 1 06/18/2011
11904 Web 1 06/18/2011
11905 Phone 1 06/19/2011
11906 Web 1 06/21/2011
12201 Web 1 05/15/2011
12201 Phone 2 06/17/2011
12202 Phone 1 06/24/2013
Legend:
= Completed diary = Missed diary = Premature discontinued
33. Daily Diary Compliance eMail
Drug Dispensing by Patient and Visit: PROTOCOL #CRW1007
Good Morning Site 4 - Philadelphia,
The following subjects did not record a diary for yesterday, Sunday, July 14.
Subject Mode Diary Status
10407 Web Not Started
10408 Web Not Started
Regards,
IVRCC Team
IVR Clinical Concepts, Inc Business Office: 358 Broadway, Suite 201 Saratoga Springs, NY
12866 Office: 561-391-9686 Website: www.ivrcc.com
LEGAL: This e-mail, including attachments, may include confidential and/or proprietary information, and may be used only by the person or entity to which it is
addressed. If the reader of this e-mail is not the intended recipient or his or her authorized agent, the reader is hereby notified that any dissemination, distribution
or copying of this e-mail is prohibited. If you have received this e-mail in error, please notify the sender by replying to this message and delete this e-mail
immediately.
34. Cumulative Diary Compliance eMail
Drug Dispensing by Patient and Visit: PROTOCOL #CRW1007
Good Day Study Staff,
This is notification of your subject's expected diary dosing calls as of June 28, 4:00 AM. Please review for action
that you may need to take to remind your subjects to record their dosing information for yesterday.
Subject Initials DOB Visit 2 Last Dose Date Diary Calls Made Diary Calls Expected
003-026 J-R 12-Dec-1979 09-May-2012 29-May-2012 20 50
003-063 J-G 08-Jan-1991 31-May-2012 31-May-2012 1 28
003-067 JJR 13-Jan-1986 07-Jun-2012 25-Jun-2012 18 21
003-071 GEM 27-Sep-1988 07-Jun-2012 26-Jun-2012 21 21
003-076 AJF 11-Oct-1989 07-Jun-2012 21-Jun-2012 10 21
Kind Regards,
IVRCC Support
IVR Clinical Concepts, Inc Business Office: 358 Broadway, Suite 201 Saratoga Springs, NY 12866 Office: 561-391-
9686 Website: www.ivrcc.com
35. SMS Text Reminders
Standard and Customized Client Reports
Drug Dispensing by Patient and Visit: PROTOCOL #CRW1007
38. Customer Care (Help Desk)
• Global staff: New York, California, Florida, Canada, Europe, South Africa,
India, Russia, Israel, and Trained Partner staff as needed: (e.g., Australia)
• Toll-free Phone: Helpdesk for 24/7/365 coverage International, or Country
phone number as needed.
– Live 8 am - 8 pm EST
– 8 PM - 8 AM via smartphone with 15 min. guaranteed turn around time
• Email Help Desk: 30 minutes during, or after start of next work day
• Ticket system: for tracking through resolution
– Prioritize issues: based upon Severity level 1 Critical (recommend phone
contact), 2 High, 3 Standard
• Auto reset: Password & User i.d.s (85% of issues)
• Online FAQ information: standard and customized per protocols
39. Thank You
IVRCC collected data enables better scientific conclusions because the
data is valid and trustworthy to regulatory authorities, which may prove
to be the difference between an approval and a request for more data
IVRCC— Providing Effective and Innovative Solutions for
Optimizing Clinical Trial Management
Editor's Notes
Font is always Arial
Primary colors are used first and then